The results show the importance of diagnosing lung conditions through spirometry as well the necessity for more effective therapies for patients without COPD. Dual bronchodilators, often prescribed ...

Although there is significant improvement in managing asthma and chronic obstructive pulmonary disease (COPD) diseases, there is still a strong need in controlling symptoms to prevent hospitalizations ...

Inhaled dual bronchodilator therapy did not decrease respiratory symptoms in former or current smokers with preserved lung function, the RETHINC trial showed. Among 535 symptomatic smokers with a 10 ...

Researchers have found that dual bronchodilators -- long-lasting inhalers that relax the airways and make it easier to breathe -- do little to help people who do not have chronic obstructive pulmonary ...

Researchers supported by the National Institutes of Health have found that dual bronchodilators - long-lasting inhalers that relax the airways and make it easier to breathe - do little to help people ...

"In patients with risk factors for COPD and respiratory symptoms, referring for spirometry is important to triage who will and won’t benefit from bronchodilators." – Meilan Han, MD, Professor of ...

The IMPACT and ETHOS trials showed that single-inhaler triple therapy significantly reduce the rate of COPD exacerbation and mortality compared with dual bronchodilators. Findings are from an ...

Synchrony Medical's LibAirty system for addressing mucus obstruction in COPD patients gained FDA clearance in July 2025.

Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...

Please provide your email address to receive an email when new articles are posted on . Inhaled dual bronchodilator therapy did not decrease respiratory symptoms among individuals who were current or ...